Kiran Mazumdar-Shaw calls for innovation-driven value creation in India's biotech sector

Published On 2024-09-13 09:43 GMT | Update On 2024-09-13 09:43 GMT

New Delhi: Biocon Chairperson Kiran Mazumdar-Shaw on Thursday called for more investment in research and development to drive innovation and foster culture of intellectual property. She highlighted how the country, already the world's largest exporter of generics and a major player in vaccine production, can achieve greater value by nurturing innovation.

Mazumdar-Shaw called for a shift in focus toward value creation through innovation. "India ranks 14th in terms of value in the global pharma landscape. We need to invest in R&D and foster a culture of intellectual property to capture greater value," she said.

Read Also: Biocon arm gets USFDA nod for chronic heart failure drug Sacubitril/Valsartan

Addressing a session during the Global Bio-India 2024 event, she positioned the country as a future global leader in biosciences and innovation.

Mazumdar-Shaw emphasized India's unique advantages in becoming a global bio-innovation hub, citing the nation's rich scientific talent, robust technological capabilities, and entrepreneurial drive.

"Biology is not only the most exciting and transformative field of our time, but it has also become the new frontier where we are pushing the boundaries of human knowledge and capability," Mazumdar-Shaw said.

She highlighted how biosciences, once confined to the laboratory, are now permeating nearly every aspect of human existence, from medicine and agriculture to environmental conservation and technology.

"We are witnessing a revolution in healthcare driven by genetics, RNA, and CRISPR technologies that offer unprecedented precision. In the near future, genetic diseases like cystic fibrosis and muscular dystrophy may be cured entirely," she said.

CRISPR is a gene editing technology that can be used to modify DNA in living organisms. She also highlighted the VIGYAN Dhara initiative, with its Rs 10,000 crore outlay aimed at promoting basic research and critical technologies.

On the agricultural front, Mazumdar-Shaw underscored the importance of biotechnology in ensuring global food security.

Mazumdar-Shaw also reflected on India's existing strengths in the global pharmaceutical sector, noting that the country is the world's third-largest manufacturer of medicines by volume and the largest exporter of generics.

"One in three pills consumed in the U.S. and one in four in the U.K. are produced in India," she stated, underscoring the scale of India's pharmaceutical production.

Read Also: Submit CT data of Liraglutide pre-filled pen for type 2 DM: CDSCO Panel Tells Biocon Pharma

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

MD Bureau Team

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Kiran Mazumdar-Shaw calls for innovation-driven value creation in India's biotech sector

Similar News

Eli Lilly gets USFDA Breakthrough Therapy designation for olomorasib with Keytruda for lung cancer

NPPA fixes Special Ceiling Price for Gufic's Meropenem Dual Chamber Bags

Sun Pharma Fails to Secure CDSCO Nod for BE, Phase III Waiver on Sitagliptin, Glimepiride, Metformin FDC

USFDA approves expanded indication for Takeda Vonvendi for adults, children with Von Willebrand Disease

Roche receives EU CE mark for Contivue for neovascular age-related macular degeneration

Drug Safety Alert: IPC Flags Adverse Reactions linked to Tranexamic acid and Metoclopramide

Virchow Biotech gets CDSCO panel nod to study Semaglutide for chronic weight management

SC Questions Effectiveness of UCPMP, Seeks Govt Clarification on Pharma Freebies